Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Amps Up T-VEC Story At ASCO With Filing Plans And Combos

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen will file the cancer immunotherapy talimogene laherparepvec for the treatment of metastatic melanoma later this year, although the product’s larger commercial potential likely lies om combination with other immunotherapies.

Advertisement

Related Content

Amgen’s T-VEC AdCom May Shed Light On How FDA Reviews Intralesional Immunotherapies
Amgen Looks To Build On Blincyto Momentum As It Enters A Year Loaded With Milestones
European Notebook: EC Pharma Policy Reorganized; Early Access To Medicines Scheme Starts; U.K. Changing Merger Regs
Amgen Wins Onyx, But Will The Deal Pave The Road To Transformation?
Amgen Plays Diversity Card In Approach To Cancer; Immunotherapy Could Be Its Ace
Amgen Gobbles Up Micromet In $1.16 Billion BiTE
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077398

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel